VRNA (Verona Pharma plc)
Insider Trading Activity
Every open-market purchase and sale reported by VRNA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-08 | Vikas Sinha | Director | MIXED | — | — |
| 2025-10-08 | James Aloysius Brady | Director | MIXED | — | — |
| 2025-10-08 | DAVID ZACCARDELLI | President and CEO | MIXED | — | — |
| 2025-10-08 | Kathleen A. Rickard | Chief Medical Officer | MIXED | — | — |
| 2025-10-08 | Mark W Hahn | Chief Financial Officer | MIXED | — | — |
| 2025-10-08 | CHRISTINA ACKERMANN | Director | MIXED | — | — |
| 2025-10-08 | Martin Edwards | Director | MIXED | — | — |
| 2025-10-08 | Lisa Deschamps | Director | MIXED | — | — |
| 2025-10-08 | Kenneth Cunningham | Director | MIXED | — | — |
| 2025-10-08 | Anders Ullman | Director | MIXED | — | — |
| 2025-10-08 | Andrew Fisher | General Counsel | MIXED | — | — |
| 2025-10-08 | Michael Austwick | Director | MIXED | — | — |
| 2025-10-08 | DAVID R EBSWORTH | Director | MIXED | — | — |
| 2025-10-08 | MAHENDRA SHAH | Director | MIXED | — | — |
| 2025-09-03 | Kathleen A. Rickard | Chief Medical Officer | G | — | — |
| 2025-09-03 | Mark W Hahn | Chief Financial Officer | G | — | — |
| 2025-09-03 | DAVID ZACCARDELLI | President and CEO | G | — | — |
| 2025-08-05 | James Aloysius Brady | Director | MIXED | — | — |
| 2025-08-05 | Andrew Fisher | General Counsel | MIXED | — | — |
| 2025-08-05 | MAHENDRA SHAH | Director | MIXED | — | — |
| 2025-08-05 | Vikas Sinha | Director | MIXED | — | — |
| 2025-08-05 | Kenneth Cunningham | Director | MIXED | — | — |
| 2025-08-05 | Anders Ullman | Director | M | — | — |
| 2025-08-05 | Kathleen A. Rickard | Chief Medical Officer | MIXED | — | — |
| 2025-08-05 | DAVID ZACCARDELLI | President and CEO | MIXED | — | — |
| 2025-08-05 | DAVID R EBSWORTH | Director | MIXED | — | — |
| 2025-08-05 | Martin Edwards | Director | MIXED | — | — |
| 2025-08-05 | Mark W Hahn | Chief Financial Officer | MIXED | — | — |
| 2025-08-05 | Michael Austwick | Director | MIXED | — | — |
| 2025-08-05 | CHRISTINA ACKERMANN | Director | MIXED | — | — |
| 2025-08-05 | Lisa Deschamps | Director | MIXED | — | — |
| 2025-07-09 | Kathleen A. Rickard | Chief Medical Officer | MIXED | — | — |
| 2025-07-09 | DAVID ZACCARDELLI | President and CEO | MIXED | — | — |
| 2025-07-09 | Andrew Fisher | General Counsel | MIXED | — | — |
| 2025-07-09 | Mark W Hahn | Chief Financial Officer | MIXED | — | — |
| 2025-06-18 | Andrew Fisher | General Counsel | M | — | — |
| 2025-06-18 | Andrew Fisher | General Counsel | MIXED | — | — |
| 2025-06-13 | Mark W Hahn | Chief Financial Officer | Sell | — | — |
| 2025-06-13 | DAVID ZACCARDELLI | President and CEO | Sell | — | — |
| 2025-05-29 | Mark W Hahn | Chief Financial Officer | Sell | — | — |
| 2025-05-29 | DAVID ZACCARDELLI | President and CEO | Sell | — | — |
| 2025-05-22 | Vikas Sinha | Director | MIXED | — | — |
| 2025-05-22 | Vikas Sinha | Director | MIXED | — | — |
| 2025-05-16 | Andrew Fisher | General Counsel | MIXED | — | — |
| 2025-05-16 | CHRISTINA ACKERMANN | Director | MIXED | — | — |
| 2025-05-08 | Kathleen A. Rickard | Chief Medical Officer | Sell | — | — |
| 2025-05-05 | DAVID ZACCARDELLI | President and CEO | MIXED | — | — |
| 2025-05-05 | Kathleen A. Rickard | Chief Medical Officer | MIXED | — | — |
| 2025-05-05 | DAVID R EBSWORTH | Director | M | — | — |
| 2025-05-05 | Mark W Hahn | Chief Financial Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 55,911,648 | — |
| — | Director | 35,294,568 | — |
| — | Director | 4,180,691 | — |
| — | Director | 4,123,091 | — |
| — | Chief Financial Officer | 3,285,280 | — |
| — | President and CEO | 3,285,280 | — |
| — | General Counsel | 2,800,407 | — |
| — | General Counsel | 931,984 | — |
| — | Director | 72,000 | — |
| — | Director | 72,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VRNA quote page; the site-wide leaderboard is on the insider transactions hub.